JP Morgan Chase
LUCD icon

JP Morgan Chase’s Lucid Diagnostics LUCD Stock Holding History

JP Morgan Chase’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64K Buy
55,648
+14,142
+34% +$18K ﹤0.01% 6076
2025
Q4 		$45.2K Buy
41,506
+5,408
+15% +$6.05K ﹤0.01% 6270
2025
Q3 		$36.5K Buy
36,098
+3,380
+10% +$3.69K ﹤0.01% 6328
2025
Q2 		$37.6K Buy
32,718
+32,672
+71,026% +$42.2K ﹤0.01% 6016
2025
Q1 		$69 Sell
46
-3
-6% -$4 ﹤0.01% 6923
2024
Q4 		$40 Sell
49
-2
-4% -$2 ﹤0.01% 7171
2024
Q3 		$42 Buy
51
+1
+2% +$1 ﹤0.01% 7148
2024
Q2 		$41 Buy
50
+16
+47% +$14 ﹤0.01% 7059
2024
Q1 		$28 Sell
34
-13
-28% -$17 ﹤0.01% 7124
2023
Q4 		$66 Buy
47
+34
+262% +$45 ﹤0.01% 7167
2023
Q3 		$15 Buy
+13
New +$19 ﹤0.01% 7230
2022
Q3 		– Sell
-566
Closed -$1K – 6683
2022
Q2 		$1K Sell
566
-1,801
-76% -$4K ﹤0.01% 6364
2022
Q1 		$8K Sell
2,367
-2,030
-46% -$7.42K ﹤0.01% 6249
2021
Q4 		$23K Buy
+4,397
New +$35.7K ﹤0.01% 6179

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

JP Morgan Chase's LUCD Position: Q1 2026 in Review

JP Morgan Chase increased its Lucid Diagnostics (LUCD) stake by 34% in Q1 2026, buying an estimated $18K and bringing the position to 55,648 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #6076.

JP Morgan Chase first reported a position in LUCD in Q4 2021 and has held it in 14 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • JP Morgan Chase held 55,648 shares of Lucid Diagnostics worth $64K as of Q1 2026.
  • JP Morgan Chase bought 14,142 Lucid Diagnostics shares in Q1 2026, an estimated $18K.
  • Lucid Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6076 holding.
  • JP Morgan Chase first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 14 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.